NCT03441048View on ClinicalTrials.gov

Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 22, 2018

Primary Completion Date

May 22, 2024

Study Completion Date

May 22, 2024

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

Lintuzumab-Ac-225

Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of relapsed/refractory acute myeloid leukemia.

DRUG

Cladribine

Cladribine is a purine antimetabolite.

DRUG

Cytarabine

Cytarabine is an antineoplastic anti-metabolite.

DRUG

Mitoxantrone

Mitoxantrone is an anthracenedione antineoplastic agent.

DRUG

G-CSF

G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells.

Trial Locations (1)

53226

Froedtert Hospital and the Medical College of Wisconsin, Milwuakee

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER

NCT03441048 - Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter